327 related articles for article (PubMed ID: 17179482)
1. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.
Arumugam T; Ramachandran V; Logsdon CD
J Natl Cancer Inst; 2006 Dec; 98(24):1806-18. PubMed ID: 17179482
[TBL] [Abstract][Full Text] [Related]
2. Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy.
Arumugam T; Ramachandran V; Sun D; Peng Z; Pal A; Maxwell DS; Bornmann WG; Logsdon CD
Mol Cancer Ther; 2013 May; 12(5):654-62. PubMed ID: 23303403
[TBL] [Abstract][Full Text] [Related]
3. S100P promotes pancreatic cancer growth, survival, and invasion.
Arumugam T; Simeone DM; Van Golen K; Logsdon CD
Clin Cancer Res; 2005 Aug; 11(15):5356-64. PubMed ID: 16061848
[TBL] [Abstract][Full Text] [Related]
4. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis.
Arumugam T; Ramachandran V; Gomez SB; Schmidt AM; Logsdon CD
Clin Cancer Res; 2012 Aug; 18(16):4356-64. PubMed ID: 22718861
[TBL] [Abstract][Full Text] [Related]
5. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
6. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
[TBL] [Abstract][Full Text] [Related]
7. [Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer].
Wang SJ; Sun B; Pan SH; Chen H; Kong R; Li J; Xue DB; Bai XW; Jiang HC
Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(7):530-4. PubMed ID: 20646665
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ
Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963
[TBL] [Abstract][Full Text] [Related]
9. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.
Pan X; Arumugam T; Yamamoto T; Levin PA; Ramachandran V; Ji B; Lopez-Berestein G; Vivas-Mejia PE; Sood AK; McConkey DJ; Logsdon CD
Clin Cancer Res; 2008 Dec; 14(24):8143-51. PubMed ID: 19088029
[TBL] [Abstract][Full Text] [Related]
11. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.
Holcomb BK; Yip-Schneider MT; Waters JA; Beane JD; Crooks PA; Schmidt CM
J Gastrointest Surg; 2012 Jul; 16(7):1333-40. PubMed ID: 22618517
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
13. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
14. Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.
Wang SJ; Gao Y; Chen H; Kong R; Jiang HC; Pan SH; Xue DB; Bai XW; Sun B
Cancer Lett; 2010 Jul; 293(1):99-108. PubMed ID: 20137856
[TBL] [Abstract][Full Text] [Related]
15. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE).
Arumugam T; Simeone DM; Schmidt AM; Logsdon CD
J Biol Chem; 2004 Feb; 279(7):5059-65. PubMed ID: 14617629
[TBL] [Abstract][Full Text] [Related]
16. In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer.
Kim CE; Lim SK; Kim JS
J Control Release; 2012 Jan; 157(2):190-5. PubMed ID: 21963773
[TBL] [Abstract][Full Text] [Related]
17. Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway.
Wang Y; Wu X; Zhou Y; Jiang H; Pan S; Sun B
Cancer Prev Res (Phila); 2016 Mar; 9(3):234-44. PubMed ID: 26667450
[TBL] [Abstract][Full Text] [Related]
18. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.
Blaauboer A; Booy S; van Koetsveld PM; Karels B; Dogan F; van Zwienen S; van Eijck CHJ; Hofland LJ
BMC Cancer; 2020 Sep; 20(1):913. PubMed ID: 32967656
[TBL] [Abstract][Full Text] [Related]
19. Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-кB pathway.
Lou C; Lu H; Ma Z; Liu C; Zhang Y
Biomed Pharmacother; 2019 Jan; 109():563-572. PubMed ID: 30399592
[TBL] [Abstract][Full Text] [Related]
20. Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
Prasad S; Yadav VR; Sung B; Gupta SC; Tyagi AK; Aggarwal BB
Oncotarget; 2016 Mar; 7(11):13182-96. PubMed ID: 26909608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
